Elevar Therapeutics

Elevar Therapeutics is a fully integrated biopharmaceutical company focused on developing and advancing therapies for patients with limited or inadequate treatment options. Rooted in oncology, the company applies its experience to identifying and developing medicines for complex, under-treated conditions across therapeutic areas. Its approach emphasizes rigorous research, evolving the potential of existing or emerging medicines, and pursuing treatments that may improve clinical outcomes and patient experiences.

Elevar’s therapeutic portfolio includes lirafugratinib, which the company reports is approved, as well as rivoceranib and camrelizumab. Its website provides information about these therapeutics, scientific publications and presentations, and ongoing pipeline activity. The company also supports investigator-initiated trials through an application process for proposals, including those related to hepatocellular carcinoma, head and neck cancers, biliary tract cancers, rare diseases, and combination regimens. In addition to research and development, Elevar offers opportunities for partnership and shares company news, events, and career information. Guided by a commitment to ethical engagement and underserved patient needs, it aims to help elevate standards of care and treatment outcomes.